WF-47-JS03

RET kinase inhibitor

orally efficacious in XG but narrow TI

from data mining of internal matter and opt.

ACS Med. Chem. Lett. Feb. 12, 2020

Novartis (GNF), San Diego, CA

(Novartis (GNF) oral in vivo RET kinase inhibitor)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.